CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Mesenchymal stem cell +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02513238
NCT02513238Phase 2Completed
CompareCT.gov

Mesenchymal Stem Cells for Radiation-induced Xerostomia (MESRIX) in Previous HPV-positive Oropharyngeal Head and Neck Cancer Patients - A Safety and Feasibility Study

Rigshospitalet, Denmark·interventional·Posted Jul 31, 2015·Updated Dec 28, 2022

In Brief

A Phase 2 clinical trial evaluating Mesenchymal stem cell and Isotonic NaCl for Xerostomia. Completed, enrolled 30 participants.

Detailed Summary

The current study aims to assess the safety and feasibility of the injection of autologous adipost tissue derived MSCs on radiation-induced salivary gland hypofunction and xerostomia in head and neck cancer participants. The project can potentially help to develop a clinically relevant treatment option for the growing number of patients suffering from xerostomia after radiotherapy. The development of new therapies is especially important, since only sub-optimal symptomatic treatments are currently available and the symptom of xerostomia greatly reduces the quality of life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsXerostomia
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 31, 2015
Enrollment StartAug 8, 2015
Primary CompletionApr 6, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.9 years ago

Interventions

Mesenchymal stem celldrug

Stemcells injected into submandibularis

Isotonic NaCldrug